This research article presents the results of the development and experimental evaluation of prolonged-release contact lenses for use in ophthalmology. The research aimed to create innovative delivery systems capable of overcoming the limitations of traditional eye drops, such as low bioavailability and the need for frequent use. Silicone hydrogel (Senofilcon A, Lotrafilcon B) and polymer (pHEMA) matrices modified with PLGA nanoparticles and cyclodextrins were used in the work to improve the solubility and controlled release of drugs (timolol maleate and cyclosporine A). The research methods included in-situ polymerization, saturation of the finished lenses, as well as physico-chemical and biological evaluation of the obtained systems. HPLC analysis and the Franz diffusion cell equipment were used to investigate the kinetics of release. The results demonstrated that silicone hydrogel lenses provide two-phase release (28.3±2.1% in 2 hours and 65.7±3.4% in 72 hours), while pHEMA+PLGA-based systems showed a more uniform profile (82.4±4.2% in 96 hours). All developed lenses retained optimal optical (>95% transmission) and mechanical properties (modulus of elasticity 0.45–0.85 MPa). Biological tests confirmed the absence of cytotoxicity (cell viability 92.4±3.1%) and a pronounced therapeutic effect in vivo (reduction of intraocular pressure by 34.7±2.8%). The study emphasises how medical contact lenses may be used to treat long-term eye conditions such dry eye syndrome and glaucoma. The findings provide new avenues for customised ophthalmic treatment with enhanced compliance and bioavailability.
